

SALKALLI- retatrutide pen 10mg injection, solution
Guangzhou Yixin Cross-border E-commerce Co., Ltd.

Active ingredient (in each 0.75 mL pen)

Retatrutide — 10 mg

Purpose

Antidiabetic / Weight management agent

Uses

To improve blood glucose control in adults with type 2 diabetes.

For long-term weight management and reduction of visceral fat in adults who are overweight or obese, with or without diabetes.

Warnings

Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists. If severe or persistent abdominal pain occurs (with or without vomiting), stop using RETATRUTIDE and contact your healthcare provider immediately.

Allergic reactions: Serious hypersensitivity reactions (including anaphylaxis) have been reported.

Stop use and seek medical attention if you develop rash, swelling, or difficulty breathing.

Severe gastrointestinal disease: RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.

Gallbladder disease: Acute gallbladder events, including cholelithiasis, have occurred. Evaluate promptly if gallbladder disease is suspected.

Hypoglycemia warning:

Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.

RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.

Pediatric use: Not for use in children.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-

administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Common: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain.

Stop use and contact a doctor if symptoms become severe or persistent.

When to stop and call your doctor

Stop using the pen and contact your physician if you experience:

- Severe or persistent abdominal pain or vomiting
- Symptoms of an allergic reaction
- Signs of pancreatitis
- Any other unexpected or severe reaction

Titration schedule:

Weeks 1–4 0.19 mL (2.5 mg) once weekly

Weeks 5–8 0.37 mL (5 mg) once weekly

Weeks 9–12 0.56 mL (7.5 mg) once weekly

Week 13 and beyond 0.75 mL (10 mg) once weekly

Directions for Use

- For subcutaneous injection only.
- Inject once weekly on the same day each week, any time of day, with or without meals.
- Recommended injection sites: abdomen, thigh, or upper arm.
- Clean the injection site with alcohol before injection.
- Rotate injection sites each week.
- Use a new needle for each injection. Do not share your pen.

Uses

- To improve blood glucose control in adults with type 2 diabetes.

- For long-term weight management and reduction of visceral fat in adults who are overweight or obese, with or without diabetes.

Warnings

Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists. If severe or persistent abdominal pain occurs (with or without vomiting), stop using RETATRUTIDE and contact your healthcare provider immediately.

Allergic reactions: Serious hypersensitivity reactions (including anaphylaxis) have been reported.

Stop use and seek medical attention if you develop rash, swelling, or difficulty breathing.

Severe gastrointestinal disease: RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.

Gallbladder disease: Acute gallbladder events, including cholelithiasis, have occurred. Evaluate promptly if gallbladder disease is suspected.

Hypoglycemia warning:

Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.

RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.

Pediatric use: Not for use in children.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Common: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain.

Stop use and contact a doctor if symptoms become severe or persistent.

When to stop and call your doctor

Stop using the pen and contact your physician if you experience:

- Severe or persistent abdominal pain or vomiting

- Symptoms of an allergic reaction
- Signs of pancreatitis
- Any other unexpected or severe reaction

stop use

Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists. If severe or persistent abdominal pain occurs (with or without vomiting), stop using RETATRUTIDE and contact your healthcare provider immediately.

Allergic reactions: Serious hypersensitivity reactions (including anaphylaxis) have been reported.

Stop use and seek medical attention if you develop rash, swelling, or difficulty breathing.

Severe gastrointestinal disease: RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.

Gallbladder disease: Acute gallbladder events, including cholelithiasis, have occurred. Evaluate promptly if gallbladder disease is suspected.

Hypoglycemia warning:

Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.

RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.

Pediatric use: Not for use in children.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Common: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain.

Stop use and contact a doctor if symptoms become severe or persistent.

When to stop and call your doctor

Stop using the pen and contact your physician if you experience:

- Severe or persistent abdominal pain or vomiting
- Symptoms of an allergic reaction
- Signs of pancreatitis
- Any other unexpected or severe reaction

Keep out of reach of children.

Keep out of reach of children

Inactive ingredients


Sterile Water for Injection

PRINCIPAL DISPLAY PANEL

10mg水剂减肥注射器-双插盒外盒
尺寸:176 x 80 x 25 mm
工艺:350g白卡过光膜, 四色印,指定位置激凸
内托:350g白卡纸折卡托





激凸版




10mg水剂减肥注射器-内包标贴
尺寸:40x15mm
工艺:合成纸不干胶, 四色印过光膜



内托:350g白卡
纸折摆放示意
尺寸根据外盒实际尺寸而定
槽尺寸深度按包材(可按实际大小调整)



10mg水剂减肥注射器-2件套封套
尺寸:176 x 82 x 51 mm
工艺:350g白卡过光膜, 四色印



176mm

51mm

82mm

Directions for Use

- For subcutaneous injection only.
- Inject once weekly on the same day each week, any time of day, with or without meals.
- Recommended injection sites: abdomen (at least 2 inches from navel), thigh, or upper arm.
- Clean the injection site with alcohol before injection.
- Rotate injection sites each week.
- Use a **new needle for each injection**. Do not share your pen.

Missed dose:

If a dose is missed, administer as soon as possible within 4 days.
If more than 4 days have passed, skip the missed dose and resume on the next scheduled day.

Titration Schedule (Start low to reduce GI side effects; volumes based on 15.3 mg/mL concentration):

Weeks	Dose	Volume (mL)	Notes
1-4	2.5 mg	0.188	Initial dose
5-8	5 mg	0.376	Increase if tolerated
9-12	7.5 mg	0.564	Further increase
13+	10 mg	0.75	Maintenance

10mg**Salkalli™** **Rx** **USA****1 Set containing 2 Cartons of
1 Prefilled Pen each****RETATRUTIDE Pen**

10 mg / 0.75 mL per prefilled pen

1 Prefilled Pen — 0.75 mL**Rx Only** For subcutaneous use only

Keep refrigerated (2 °C – 8 °C / 36 °F – 46 °F)
Protect from light • Do not freeze
Single patient use only
Keep out of reach of children

**Salkalli™****How Supplied****1 Set containing 2 Cartons of 1 Prefilled Pen each**

- 10 mg / 0.75 mL per multi-dose prefilled pen
 - Each carton contains 1 prefilled pen and 4 sterile disposable needles
- Each pen contains multiple doses (up to 4 injections).**
Use a **new sterile needle** for each injection.

Do not reuse needles.

Discard the needle safely after every injection.
Discard the pen after completion of all 4 doses or upon expiration.

**Storage and Handling**

- Store at 2 °C – 8 °C (36 °F – 46 °F)
- Do not freeze.
- Protect from light; keep pen in original carton until use.
- Keep the pen capped and refrigerated between uses.
- Discard pen if frozen, discolored, or containing particles.

Manufactured for:

Salkalli™
[Company Name and Address]
For product inquiries: [Phone Number]
www.xxx.com

NDC XXXXX-XXX-XX

Drug Facts**Active ingredient (in each 0.75 mL pen)**

Retatrutide — 10 mg Antidiabetic / Weight management agent

Uses

- To improve blood glucose control in adults with type 2 diabetes.
- For long-term weight management and reduction of visceral fat in adults who are overweight or obese, with or without diabetes.

Warnings**Pancreatitis:**

Acute pancreatitis has been reported with GLP-1 receptor agonists. If severe or persistent abdominal pain occurs (with or without vomiting), stop using RETATRUTIDE and contact your healthcare provider immediately.

Allergic reactions:

Serious hypersensitivity reactions (including anaphylaxis) have been reported. Stop use and seek medical attention if you develop rash, swelling, or difficulty breathing.

Severe gastrointestinal disease:

RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.

Gallbladder disease:

Acute gallbladder events, including cholelithiasis, have occurred. Evaluate promptly if gallbladder disease is suspected.

Hypoglycemia warning:

Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy and breastfeeding:

Do not use if pregnant or breastfeeding.

Pediatric use:

Not for use in children.

Drug Interactions / Precautions

- **Other antidiabetic medications:** Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
- **Drugs affecting gastrointestinal motility:** Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
- **Cardiovascular medications:** Caution with statins, digoxin, or warfarin.
 - Statins: absorption may be affected; monitor lipid levels.
 - Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.
- **General precautions:** Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Common: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain. Stop use and contact a doctor if symptoms become severe or persistent.

When to stop and call your doctor

Stop using the pen and contact your physician if you experience:

- Severe or persistent abdominal pain or vomiting
- Symptoms of an allergic reaction
- Signs of pancreatitis
- Any other unexpected or severe reaction

Inactive ingredients


Sterile Water for Injection

Other information

- Store refrigerated at 2 °C – 8 °C (36 °F – 46 °F).
- Protect from light; keep in carton until ready to use.
- Do not freeze.
- Single patient use only — discard the pen 30 days after first use or when empty, whichever comes first.

10mg水剂减肥注射器-3件套封套
尺寸:176 x 82 x 77 mm
工艺:350g白卡过光膜, 四色印

根据盒子调合适封套



176mm

77mm

82mm

Directions for Use

- For subcutaneous injection only.
- Inject once weekly on the same day each week, any time of day, with or without meals.
- Recommended injection sites: abdomen (at least 2 inches from navel), thigh, or upper arm.
- Clean the injection site with alcohol before injection.
- Rotate injection sites each week.
- Use a **new needle for each injection**. Do not share your pen.

Missed dose:

If a dose is missed, administer as soon as possible within 4 days.
If more than 4 days have passed, skip the missed dose and resume on the next scheduled day.

Titration Schedule (Start low to reduce GI side effects;
volumes based on 15.3 mg/mL concentration):

Weeks	Dose	Volume (mL)	Notes
1-4	2.5 mg	0.188	Initial dose
5-8	5 mg	0.376	Increase if tolerated
9-12	7.5 mg	0.564	Further increase
13+	10 mg	0.75	Maintenance

10mg

Salkalli™

Rx

USA

RETATRUTIDE Pen

10 mg / 0.75 mL per prefilled pen


1 Prefilled Pen — 0.75 mL

Rx Only

For subcutaneous use only

Keep refrigerated (2 °C – 8 °C / 36 °F – 46 °F)
Protect from light • Do not freeze
Single patient use only
Keep out of reach of children

1 Set containing 3 Cartons of
1 Prefilled Pen each



Salkalli™

How Supplied

1 Set containing 3 Cartons of 1 Prefilled Pen each

- 10 mg / 0.75 mL per multi-dose prefilled pen
- Each carton contains 1 prefilled pen and 4 sterile disposable needles

Each pen contains multiple doses (up to 4 injections).

Use a **new sterile needle** for each injection.

Do not reuse needles.

Discard the needle safely after every injection.
Discard the pen after completion of all 4 doses or upon expiration.


Storage and Handling


- Store at 2 °C – 8 °C (36 °F – 46 °F)
- Do not freeze.
- Protect from light; keep pen in original carton until use.
- Keep the pen capped and refrigerated between uses.
- Discard pen if frozen, discolored, or containing particles.

Manufactured for:


Salkalli™
[Company Name and Address]
For product inquiries: [Phone Number]
www.xxx.com

NDC XXXXX-XXX-XX





根据盒子调合适封套



176mm

102mm

Directions for Use

- For subcutaneous injection only.
- Inject once weekly on the same day each week, any time of day, with or without meals.
- Recommended injection sites: abdomen (at least 2 inches from navel), thigh, or upper arm.
- Clean the injection site with alcohol before injection.
- Rotate injection sites each week.
- Use a **new needle for each injection**. Do not share your pen.

Missed dose:

Missed dose:
If a dose is missed, administer as soon as possible within 4 days.
If more than 4 days have passed, skip the missed dose and resume on the next scheduled day.

Titration Schedule (Start low to reduce GI side effects; volumes based on 13.3 mg/mL concentration):

Weeks	Dose	Volume (mL)	Notes
1-4	2.5 mg	0.188	Initial dose
5-8	5 mg	0.376	Increase if tolerated
9-12	7.5 mg	0.564	Further increase
13+	10 mg	0.75	Maintenance

82mm

10mg

Salkalli™ Rx USA

1 Set containing 4 Cartons of
1 Prefilled Pen each

RETATRUTIDE Pen

10 mg / 0.75 mL per prefilled pen

1 Prefilled Pen — 0.75 mL

Rx Only For subcutaneous use only

Keep refrigerated (2 °C – 8 °C / 36 °F – 46 °F)
Protect from light • Do not freeze
Single patient use only
Keep out of reach of children



Salkalli™

How Supplied

1 Set containing 4 Cartons of 1 Prefilled Pen each
• 10 mg / 0.75 mL per multi-dose prefilled pen
• Each carton contains 1 prefilled pen and 4 sterile disposable needles
Each pen contains multiple doses (up to 4 injections).
Use a new sterile needle for each injection.
Do not reuse needles.
Discard the needle safely after every injection.
Discard the pen after completion of all 4 doses or upon expiration.

Storage and Handling

• Store at 2 °C – 8 °C (36 °F – 46 °F)
• Do not freeze.
• Protect from light; keep pen in original carton until use.
• Keep the pen capped and refrigerated between uses.
• Discard pen if frozen, discolored, or containing particles.

Manufactured for:

Salkalli™
[Company Name and Address]
For product inquiries: [Phone Number]
www.xxx.com
NDC XXXXX-XXX-XX



Drug Facts

Active ingredient (in each 0.75 mL pen) Retatrutide — 10 mg
Purpose Antidiabetic / Weight management agent

Uses

• To improve blood glucose control in adults with type 2 diabetes.
• For long-term weight management and reduction of visceral fat in adults who are overweight or obese, with or without diabetes.

Warnings

Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists. If severe or persistent abdominal pain occurs (with or without vomiting), stop using RETATRUTIDE and contact your healthcare provider immediately.

Allergic reactions: Serious hypersensitivity reactions (including anaphylaxis) have been reported. Stop use and seek medical attention if you develop rash, swelling, or difficulty breathing.

Severe gastrointestinal disease: RETATRUTIDE has not been studied in patients with severe GI disorders; use is not recommended.

Gallbladder disease: Acute gallbladder events, including cholelithiasis, have occurred. Evacuate promptly if gallbladder disease is suspected.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.

Pediatric use:

Not for use in children.

Drug Interactions / Precautions

• Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
• Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
• Cardiovascular medications: Caution with statins, digoxin, or warfarin.
○ Statins: absorption may be affected; monitor lipid levels.
○ Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.
• General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Common: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, abdominal pain. Stop use and contact a doctor if symptoms become severe or persistent.

When to stop and call your doctor

Stop using the pen and contact your physician if you experience:
• Severe or persistent abdominal pain or vomiting
• Symptoms of an allergic reaction
• Signs of pancreatitis
• Any other unexpected or severe reaction

Inactive ingredients

Sterile Water for Injection

Other information

• Store refrigerated at 2 °C – 8 °C (36 °F – 46 °F).
• Protect from light; keep in carton until ready to use.
• Do not freeze.
• Single patient use only — discard the pen 30 days after first use or when empty, whichever comes first.

SALKALLI

retatrutide pen 10mg injection, solution

Product Information					
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)		NDC:84778-111
Route of Administration		SUBCUTANEOUS			
Active Ingredient/Active Moiety					
Ingredient Name				Basis of Strength	Strength
RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV)				RETATRUTIDE	10 mg in 1 mL
Inactive Ingredients					
Ingredient Name				Strength	
AQUA (UNII: 059QF0KO0R)					
Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:84778-111-01	1 in 1 CARTON	10/29/2025		
1		0.75 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)			
2	NDC:84778-111-02	2 in 1 PACKAGE, COMBINATION	10/29/2025		
2		1 in 1 CARTON			
2		0.75 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)			
3	NDC:84778-111-03	3 in 1 PACKAGE, COMBINATION	10/29/2025		
3		1 in 1 CARTON			
3		0.75 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)			
4	NDC:84778-111-04	4 in 1 PACKAGE, COMBINATION	10/29/2025		
4		1 in 1 CARTON			
4		0.75 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)			
Marketing Information					
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
Export only			10/29/2025		

Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Establishment			
Name	Address	ID/FEI	Business Operations
Guangzhou Yixin Cross-border E-commerce Co., Ltd.		455800881	label(84778-111) , manufacture(84778-111)

Revised: 11/2025

Guangzhou Yixin Cross-border E-commerce Co., Ltd.